Identification of a prognostic chemoresistance-related gene signature associated with immune microenvironment in breast cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Zaheed M, Wilcken N, Willson ML, et al. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst Rev. 2019;2:D12873.
   Google Scholar
• Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc. 2009;84(6):533–545.
   PubMed Web of Science ®Google Scholar
• Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician. 2010;81(11):1339–1346.
   PubMed Web of Science ®Google Scholar
• Ji X, Lu Y, Tian H, et al. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800.
   PubMed Web of Science ®Google Scholar
• Nedeljkovic M, Damjanovic A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells-Basel. 2019;8(9):957.
   Google Scholar
• Li J, Liu C, Chen Y, et al. Tumor characterization in breast cancer identifies immune-relevant gene signatures associated with prognosis. Front Genet. 2019;10:1119.
   PubMed Web of Science ®Google Scholar
• Velaei K, Samadi N, Barazvan B, et al. Tumor microenvironment-mediated chemoresistance in breast cancer. Breast. 2016;30:92–100.
   PubMed Web of Science ®Google Scholar
• Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5(10):588–599.
   PubMedGoogle Scholar
• Chen B, Tang H, Chen X, et al. Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer. Cancer Manag Res. 2019;11:179–190.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Zhang Z, et al. A four-gene signature predicts the efficacy of paclitaxel-based neoadjuvant therapy in human epidermal growth factor receptor 2-negative breast cancer. J Cell Biochem. 2019;120(4):6046–6056.
   PubMed Web of Science ®Google Scholar
• Ragusa M, Avola G, Angelica R, et al. Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy. Bmc Cancer. 2010;10:377.
   PubMed Web of Science ®Google Scholar
• Chen X, Jiang W, Wang Q, et al. Systematically characterizing and prioritizing chemosensitivity related gene based on Gene Ontology and protein interaction network. Bmc Med Genomics. 2012;5:43.
   PubMed Web of Science ®Google Scholar
• Ren P, Wang J, Li L, et al. Identification of key genes involved in the recurrence of glioblastoma multiforme using weighted gene co-expression network analysis and differential expression analysis. Bioengineered. 2021;12(1):3188–3200.
   PubMed Web of Science ®Google Scholar
• Runa F, Hamalian S, Meade K, et al. Tumor microenvironment heterogeneity: challenges and opportunities. Curr Mol Biol Rep. 2017;3(4):218–229.
   PubMedGoogle Scholar
• Li Z, Li Y, Wang X, et al. Identification of a six-immune-related long non-coding RNA signature for predicting survival and immune infiltrating status in breast cancer. Front Genet. 2020;11:680.
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41(Database issue):D991–D995.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Wickham H. ggplot2:elegantgraphics for data analysis. 2nd ed. 2016. Springer, New York.
   Google Scholar
• Harris MA, Clark J, Ireland A, et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004;32(Databaseissue):D258–D261.
   PubMedGoogle Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
   PubMed Web of Science ®Google Scholar
• Sehhati MR, Dehnavi AM, Rabbani H, et al. Using protein interaction database and support vector machines to improve gene signatures for prediction of breast cancer recurrence. J Med Signals Sens. 2013;3(2):87–93.
   PubMedGoogle Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. Bmc Bioinformatics. 2008;9:559.
   PubMed Web of Science ®Google Scholar
• Chen L, Yuan L, Qian K, et al. Identification of biomarkers associated with pathological stage and prognosis of clear cell renal cell carcinoma by co-expression network analysis. Front Physiol. 2018;9:399.
   PubMed Web of Science ®Google Scholar
• Botia JA, Vandrovcova J, Forabosco P, et al. An additional k-means clustering step improves the biological features of WGCNA gene co-expression networks. Bmc Syst Biol. 2017;11(1):47.
   PubMedGoogle Scholar
• Yuan L, Qian G, Chen L, et al. Co-expression network analysis of biomarkers for adrenocortical carcinoma. Front Genet. 2018;9:328.
   PubMed Web of Science ®Google Scholar
• Bovelstad HM, Nygard S, Storvold HL, et al. Predicting survival from microarray data–a comparative study. Bioinformatics. 2007;23(16):2080–2087.
   PubMed Web of Science ®Google Scholar
• Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26(30):5512–5528.
   PubMed Web of Science ®Google Scholar
• Wang X, Li T. Development of a 15-gene signature for predicting prognosis in advanced colorectal cancer. Bioengineered. 2020;11(1):165–174.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang L, Wu Y, et al. Genome-wide study of key genes and scoring system as potential noninvasive biomarkers for detection of suicide behavior in major depression disorder. Bioengineered. 2020;11(1):1189–1196.
   PubMed Web of Science ®Google Scholar
• Huang R, Mao M, Lu Y, et al. A novel immune-related genes prognosis biomarker for melanoma: associated with tumor microenvironment. Aging (Albany NY). 2020;12(8):6966–6980.
   PubMedGoogle Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Li N, Zheng Z, et al. Screening of key biomarkers and immune infiltration in pulmonary arterial hypertension via integrated bioinformatics analysis. Bioengineered. 2021;12(1):2576–2591.
   PubMed Web of Science ®Google Scholar
• Chen SY, Hu SS, Dong Q, et al. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo. Asian Pac J Cancer Prev. 2013;14(10):6135–6140.
   PubMedGoogle Scholar
• Shen H, Li L, Yang S, et al. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3beta signaling pathway. Gene. 2016;593(1):84–90.
   PubMed Web of Science ®Google Scholar
• Cleall S. Modelling survival data in medical research (second edition) Collett D (2003) ISBN 1584883251; 408 pages; CRC Press. Pharm Stat. 2004;3(1):69. http://www.crcpress.com/
   Google Scholar
• Torre LA, Islami F, Siegel RL, et al. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444–457.
   PubMed Web of Science ®Google Scholar
• Adnan N, Liu Z, Huang T, et al. Comparative evaluation of network features for the prediction of breast cancer metastasis. Bmc Med Genomics. 2020;13(Suppl 5):40.
   PubMedGoogle Scholar
• Meng Z, Liu Y, Wang J, et al. Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer. J Cell Physiol. 2020;235(2):932–943.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Taira N, Hara F, et al. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res. 2010;12(3):R43.
   PubMed Web of Science ®Google Scholar
• Wang X, Wan J, Xu Z, et al. Identification of competitive endogenous RNAs network in breast cancer. Cancer Med. 2019;8(5):2392–2403.
   PubMed Web of Science ®Google Scholar
• Ye Q, Han X, Wu Z. Bioinformatics analysis to screen key prognostic genes in the breast cancer tumor microenvironment. Bioengineered. 2020;11(1):1280–1300.
   PubMed Web of Science ®Google Scholar
• Ali HR, Chlon L, Pharoah PD, et al. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. Plos Med. 2016;13(12):e1002194.
   PubMed Web of Science ®Google Scholar